Chattem explores homeopathy
This article was originally published in The Tan Sheet
Firm "is working to develop alternate formulations for Sportscreme and Aspercreme" in case FDA does not look favorably on available clinical data for active ingredient trolamine salicylate, Chattem says in recent 10-K filing. Firm also states it could market the pain relief products as homeopathic agents, or submit new studies on ingredient's safety and efficacy. In May 2001, FDA recommended Chattem adjust the protocol for a proposed study to more accurately reflect the actual use of topical analgesics (1"The Tan Sheet" May 7, 2001, p. 4)...
You may also be interested in...
Chattem should consider allowing study subjects to apply 10% trolamine salicylate cream to any painful joints or muscles, although efficacy studies could focus only on a single joint or muscle, FDA Division of OTC Drug Products Director Charles Ganley, MD, said at a May 1 feedback meeting.
Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.
In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.